Navegando por Palavras-chave "cd127"

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Avaliação dos linfócitos t cd4+ctla-4+ e do receptor da il-7 (il-7r cd127) ao diagnóstico e após o tratamento de pacientes com linfoma de hodgkin clássico
    (Universidade Federal de São Paulo (UNIFESP), 2014-05-28) Silva, Joyce Matie Kinoshita da [UNIFESP]; Baiocchi, Otavio Carvalho Guimarães [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    The interaction of EBV and RS cells contribute for cytokines/chemokines expression in the microenvironment. It is believed that IL-7 and IL-7 receptor (IL-7R?; CD127) roles in lymphoid tumor pathogeneses. Regulatory T cells (T reg cells) are suppressive CD4+ cells involved role in immunosuppression of immune reactions like autoimmunity, allergy and immunopathology. CTLA-4 is one of the marker that have also been recognized as regulatory T cells, potentially decreasing antitumor immune response. Augmentation of the immune response via blockade CTLA-4 has shown an improvement in survival for patients with metastatic melanoma, which prompted the Food and Drug Administration (FDA) approval of the CTLA-4 function blocking antibody Ipilimumab for this disease. Purpose: We aimed to evaluate the expression of CTLA-4 and CD127 on CD4+ T cells in peripheral blood mononuclear cells (PBMC) of patients with classical Hodgkin lymphoma (cHL) and the impact of treatment on these cells and correlate these findings with clinical and epidemiological aspects. Patients and Methods: Peripheral blood from 19 healthy individuals and 34 patients with classical Hodgkin?s lymphoma was obtained after informed consent. Patients were submitted to treatment (quimiotherapy and/or radiotherapy) and after one month finished the treatment another sample of peripheral blood was obtained. All patients were HIV negative. Phenotype of regulatory T cells was done by flow cytometry using CD3, CD127, CD4, CTLA-4-PE, CD25. Samples were acquired using the Cell-Quest software and by FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Results: From the 34 cHL patients recruited for this study, 17 (50%) were male, 16 (47%) had Epstein-Barr virus (EBV) related cHL, 27 (79%) patients presented with B symptoms and 19 (56%) patients had advanced diseases at diagnosis. The percentage of CTLA-4 expression on CD4+ T cells was significantly increased in patients with cHL at diagnosis compared with healthy controls [median 8.7 (1.9 ? 43.83) vs 2.5 (0.7 ? 26.2); p<0.001]. Additionally, the frequency of this population decreased significantly following treatment [8.7 (1.9 ? 43.83) vs 3.9 (1.5 - 30.3); p=0.043], with values similar to healthy controls (3.9 vs 2.5; p=0.009). By contrast, the frequency of CD127 expression on CD4+ T lymphocytes was decreased at diagnosis, with values increasing after therapy [41.2 (3.3 ? 75.0) vs 53.9 (17.1 ? 81.3); p=0.002], similar to healthy controls [53.9 (17.1 ? 81.3) vs 58.2 (41.2 ? 89.8); p=0.21]. The frequencies of these cells were not correlated with age, gender, disease stage, erythrocyte sedimentation rate (ESR), albumin levels and EBV status. Conclusion: In this study we showed that treatment play an important role in the immunological system of these patients reestablishment. The treatment help to decrease the expression of CTLA-4 that was found increased in the moment of diagnose comparing to healthy control, and help to increase the expression of CD127 that was decreased at diagnosis. Our data have clinical implication because the promising immunotherapy regimen targeting CTLA-4 and the use of drugs that alter CD127 signaling might be beneficial in classical Hodgkin lymphoma.